Lenalidomide in the treatment of chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Lenalidomide in the treatment of chronic lymphocytic leukemia

Published:2011-01-10 Issue:2 Volume:20 Page:273-286
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Gentile Massimo,Recchia Anna Grazia,Vigna Ernesto,Mazzone Carla,Lucia Eugenio,Gigliotti Vincenzo,Bossio Sabrina,Madeo Antonio,Morabito Lucio,Servillo Pasquale,Franzese Stefania,Caruso Nadia,De Stefano Laura,Bisconte Maria Grazia,Gentile Carlo,Morabito Fortunato

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1517/13543784.2011.546343

Reference93 articles.

1. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

2. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

3. Catovsky D, Foa R. The lymphoid leukaemias. Butterworths, London; 1990

4. Clinical Characteristics and Outcome of Young Chronic Lymphocytic Leukemia Patients: A Single Institution Study of 204 Cases

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population pharmacokinetics of lenalidomide in patients with B‐cell malignancies;British Journal of Clinical Pharmacology;2019-02-27

2. Lenalidomide in chronic lymphocytic leukemia;Expert Opinion on Orphan Drugs;2016-07-28

3. The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines;Hematological Oncology;2014-11-13

4. Lenalidomide in lymphomas and chronic lymphocytic leukemia;Expert Opinion on Pharmacotherapy;2013-01-29

5. MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies;ISRN Hematology;2013-01-29